Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Outcomes and Risk Factors of Kidney Transplantation from Pediatric Donors to Adult Recipients
G. Chen, X. Liu, C. Wang, Z. Wu, C. Wang, L. Chen.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Objective To investigate the outcomes of kidney transplantation from pediatric donors to adult recipients, and explore the risk factors for DGF and graft loss after…
2018 American Transplant Congress
Having Your Cake and Eating It Too: An Aggressive Protocol for DSA Treatment Does Not Doom Patients to High Infectious Risk
A. Murthy, A. Karaballa, G. Vranic, B. Javaid, J. Moore, S. Yi, J. Verbesey, P. Abrams, S. Ghasemian, M. Cooper, A. Gilbert.
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
Introduction: Antibody mediated rejection (AMR) is one of the most difficult complications to treat in kidney transplantation. We previously reported on our experience with an…
2018 American Transplant Congress
The Effects of Age-Adjusted Marriage Duration on Graft Outcomes in Spousal Donor Kidney Transplantation
M. Yu,¹ J. Park,² H. Cho,¹ J. Ha,¹ C. Ahn,¹ Y. Kim,¹ H. Lee.¹
¹Seoul National University Hospital, Seoul, Korea; ²Kangwon National University Hospital, Chuncheon, Korea.
It is well known that graft survival rate in spousal donor kidney transplantation (SKT) is similar to that of living related donor kidney transplantation (LRKT)…
2018 American Transplant Congress
Belatacept-Refractory CD8⁺CD28^–CD38^hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L
C. Castro Rojas,¹ A. Godarova,¹ A. Rike Shields,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
¹Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ²Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH; ³Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Research Foundation, Cincinnati, OH.
Calcineurin inhibitors (CNIs) and corticosteroids (CSS) have substantial untoward side effects, most notably nephrotoxicity. Consequently, the FDA approved belatacept for maintenance immunosuppression. We recently completed…
2018 American Transplant Congress
Precision (re)Phenotyping of Histologically Stable Kidney Transplants
D. Rychkov,¹ T. Sigdel,² M. Sirota,¹ M. Sarwal.²
¹Institute for Computational Health Sciences, UCSF, San Francisco, CA; ²Department of Surgery, UCSF, San Francisco, CA.
Background: Acute Rejection (AR) is the main cause of the renal failure within one year after transplantation (tx). Its earlier diagnosis is crucial for a…
2018 American Transplant Congress
The Role of Donor-Derived Cell-Free DNA in Identification of Injury in Kidney Allografts with Antibody-Mediated Rejection and De Novo DSA
H. Zhang,¹ L. Liu,¹ C. Zheng,² X. Li,¹ Q. Fu,¹ J. Li,¹ Q. Su,¹ H. Huang,¹ M. Ye,² C. Wang.¹
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²BGI-Guangzhou Medical Laboratory, BGI-Shenzhen, Guangzhou, China.
Objectives: To evaluate the capacity of donor-derived cell-free DNA (dd-cfDNA) in the identification of injury in kidney allografts with antibody-mediated rejection and de novo DSA.Methods:…
2018 American Transplant Congress
Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
B. Nashan,¹ C. Sommerer,¹ B. Suwelack,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was designed to compare efficacy, safety and outcomes on renal function [GFR] of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A…
2018 American Transplant Congress
Recurrent FSGS Post-Transplantation: Prevalence and Risk Factors
R. Aguiar,¹ A. Gasparini,² P. Chowdhury,¹ D. Game,¹ D. Moutzouris.¹
¹Department of Nephrology and Transplantation, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; ²Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
Introduction: Primary FSGS can recur in the renal allograft and is associated with poor outcomes. The aim of this study was to assess the prevalence…
2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
J. Shoji, J. Leung, E. Tavares, Q. Tang, F. Vincenti.
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…
2018 American Transplant Congress
Gut Microbiota, Mycophenolate Mofetil, and Post-Transplant Diarrhea in Kidney Transplant Recipients
J. Lee,¹ M. Magruder,¹ L. Zhang,¹ D. Dadhania,¹ M. Satlin,¹ L. Westblade,¹ A. Robertson,¹ Y. Taur,² L. Ling,² E. Pamer,² M. Suthanthiran.¹
¹Weill Cornell Medicine, New York, NY; ²Memorial Sloan Kettering, New York, NY.
INTRODUCTION. The etiology of post-transplant diarrhea is often unknown and attributed to mycophenolate mofetil dosage.METHODS. We recruited 71 kidney transplant recipients for serial collection of…